Literature DB >> 26043219

3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review.

Marc De Braekeleer1,2,3, Marie-Josée Le Bris3, Etienne De Braekeleer4, Audrey Basinko2,3, Frédéric Morel1,2,3, Nathalie Douet-Guilbert1,2,3.   

Abstract

The EVI1 gene, located in chromosomal band 3q26, is a transcription factor that has stem cell-specific expression pattern and is essential for the regulation of self-renewal of hematopoietic stem cells. It is now recognized as one of the dominant oncogenes associated with myeloid leukemia. EVI1 overexpression is associated with minimal to no response to chemotherapy and poor clinical outcome. Several chromosomal rearrangements involving band 3q26 are known to induce EVI1 overexpression. They are mainly found in acute myeloid leukemia and blastic phase of Philadelphia chromosome-positive chronic myeloid leukemia, more rarely in myelodysplastic syndromes. They include inv(3)(q21q26), t(3;3)(q21;q26), t(3;21)(q26;q22), t(3;12)(q26;p13) and t(2;3)(p15-23;q26). However, many other chromosomal rearrangements involving 3q26/EVI1 have been identified. The precise molecular event has not been elucidated in the majority of these chromosomal abnormalities and most gene partners remain unknown.

Entities:  

Keywords:  EVI1; breakpoint distribution; chromosomal abnormalities; chromosome 3; myeloid hemopathies

Mesh:

Substances:

Year:  2015        PMID: 26043219     DOI: 10.2217/fon.15.64

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  8 in total

1.  3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Zhihong Hu; L Jeffrey Medeiros; Wei Wang; Zi Chen; Guilin Tang; Parsa Hodjat; Su Yang; Lianghua Fang; Yan Li; Srdan Verstovsek; Shimin Hu
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

2.  Clinical and Genomic Profiles of Korean Patients with MECOM Rearrangement and the t(3;21)(q26.2;q22.1) Translocation.

Authors:  Jikyo Lee; Sung Min Kim; Soonok Kim; Jiwon Yun; Dajeong Jeong; Young Eun Lee; Eun-Youn Roh; Dong Soon Lee
Journal:  Ann Lab Med       Date:  2022-09-01       Impact factor: 4.941

3.  Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.

Authors:  Arash Ronaghy; Shimin Hu; Zhenya Tang; Wei Wang; Guilin Tang; Sanam Loghavi; Shaoying Li; Beenu Thakral; L Jeffrey Medeiros; Tariq Muzzafar
Journal:  Mod Pathol       Date:  2020-10-27       Impact factor: 7.842

4.  Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies.

Authors:  Zhenya Tang; Guilin Tang; Shimin Hu; Keyur P Patel; C Cameron Yin; Wei Wang; Pei Lin; Gokce A Toruner; Chi Y Ok; Jun Gu; Xinyan Lu; Joseph D Khoury; L Jeffrey Medeiros
Journal:  Data Brief       Date:  2019-05-23

5.  EVI1 as a Marker for Lymph Node Metastasis in HNSCC.

Authors:  Christian Idel; Julika Ribbat-Idel; Patrick Kuppler; Rosemarie Krupar; Anne Offermann; Wenzel Vogel; Dirk Rades; Jutta Kirfel; Barbara Wollenberg; Sven Perner
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

Review 6.  Acute Myeloid Leukemia-Genetic Alterations and Their Clinical Prognosis.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia; Miguel Ángel Gómez-Guijosa; Carlos Cortes-Penagos
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-10-01

7.  Acute myeloid leukemia with 3q26 abnormality: An editorial perspective.

Authors:  K Ghosh
Journal:  J Postgrad Med       Date:  2018 Apr-Jun       Impact factor: 1.476

8.  Role of miR-96/EVI1/miR-449a Axis in the Nasopharyngeal Carcinoma Cell Migration and Tumor Sphere Formation.

Authors:  Lai-Sheung Chan; Hong-Lok Lung; Roger Kai-Cheong Ngan; Anne Wing-Mui Lee; Sai Wah Tsao; Kwok-Wai Lo; Michael Kahn; Maria Li Lung; Rotraud Wieser; Nai-Ki Mak
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.